More Than Inflammation: What Makes AhR Different?

As new nonsteroidal topical therapies continue to reshape the management of inflammatory skin disease, understanding why they work has become just as important as knowing that they work. In this discussion, April Armstrong, MD, explores the aryl hydrocarbon receptor (AhR) pathway and explains why it represents more than another anti-inflammatory mechanism. From immune modulation and barrier restoration to antioxidant activity, she connects the biology of AhR agonism to the clinical outcomes dermatologists see in practice.

"Think about AhR...it's not a single inflammatory switch," says Dr Armstrong. Instead, she describes a pathway that helps restore skin homeostasis through multiple complementary mechanisms, offering insight into how tapinarof differs from traditional topical therapies and what that distinction may mean for long-term disease management, steroid stewardship, and patient care.